Showing results (1721-1730 of 2,037) with videos related to

Sort By:
Pageof 204
Urologic Oncology|March 15, 2011
A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancerYoung E Whang, Andrew J Armstrong, W Kimryn Rathmell, et al.
The Journal of Urology|November 18, 2011
Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate CenterSuzanne Biehn Stewart, Lionel L Bañez, Cary N Robertson, et al.
Dementia and Geriatric Cognitive Disorders Extra|September 11, 2012
Roles of Education and IQ in Cognitive Reserve in Parkinson's Disease-Mild Cognitive ImpairmentM J Armstrong, G Naglie, S Duff-Canning, et al.
Experimental & Molecular Medicine|July 18, 2024
Accelerated aging of skeletal muscle and the immune system in patients with chronic liver diseaseThomas Nicholson, Amritpal Dhaliwal, Jonathan I Quinlan, et al.
Cancer Research Communications|September 25, 2024
Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-TMichael C Brown, Vincent M D'Anniballe, David Boczkowski, et al.
The European Respiratory Journal|June 23, 2009
Measuring airway dimensions during bronchoscopy using anatomical optical coherence tomographyJ P Williamson, J J Armstrong, R A McLaughlin, et al.
The Prostate|March 14, 2022
Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancerTian Zhang, Julie Kephart, Elizabeth Bronson, et al.
Biomarker Research|February 19, 2021
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancerTian Zhang, Anika Agarwal, R Garland Almquist, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 7, 2012
The pill questionnaire in a nondemented Parkinson's disease populationWilliam Reginold, Melissa J Armstrong, Sarah Duff-Canning, et al.
BJU International|December 5, 2013
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancerGuru Sonpavde, Gregory R Pond, Andrew J Armstrong, et al.
Pageof 204